Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 6/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | USP19 | O94966 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | CCKBR | P32239 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13041641 | 0.93 | BRD4 (0.41) | OPRL1OPRM1OPRK1BRD4DPP4 | |
| SCHEMBL13041639 | 0.78 | PARP1 (0.43) | OPRL1OPRM1OPRK1DPP4 | |
| SCHEMBL13041630 | 0.77 | ALDH1A1 (0.43) | OPRL1OPRM1MEN1KMT2ADRD2 | |
| SCHEMBL13041625 | 0.76 | ALDH1A1 (0.39) | OPRL1OPRM1DPP4 | |
| SCHEMBL13041636 | 0.76 | C5AR1 (0.45) | OPRL1OPRM1OPRK1KMT2ARAB9A | |
| SCHEMBL13041631 | 0.76 | ENPP2 (0.51) | OPRL1OPRM1OPRK1KMT2ABRD4 | |
| SCHEMBL13041643 | 0.74 | ALOX15 (0.36) | OPRL1OPRM1MEN1KMT2ADRD2 | |
| SCHEMBL13041635 | 0.74 | PARP1 (0.43) | KMT2AMAPTNPSR1 | |
| SCHEMBL13041634 | 0.74 | PARP1 (0.43) | MEN1KMT2ADRD2MAPTRAB9A | |
| SCHEMBL13041640 | 0.73 | PARP1 (0.44) | DRD2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | ASTRAZENECA UK LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | ASTRAZENECA UK LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | RB1, RPP30, SARS1 | OPRL1 2977/4885OPRM1 1102/4885OPRK1 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.